UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

(Amendment No. 2)

Under the Securities Exchange Act of 1934

TONIX PHARMACEUTICALS HOLDING CORP.

(Name of Issuer)
Common Shares
(Title of Class of Securities)
890260409
(CUSIP Number)
December 31, 2017
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed: □ Rule 13d-1(b) □ Rule 13d-1(c) □ Rule 13d-1(d)

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

^{*} The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

CUSIP No. 890260409	13G/A	Page 2 of 8 Pages				
	OF REPORTING PERSONS NTIFICATION NOS. OF ABOVE PERSONS (ENTITIE:	S ONLY)				
Rosalind	Advisors, Inc.					
2. CHECK	HE APPROPRIATE BOX IF A MEMBER OF A GROUP)				
(see instru (a) □	(see instructions)					
(a) \Box (b) \Box						
3. SEC USE	ONLY					
4. CITIZEN	SHIP OR PLACE OF ORGANIZATION					
ONTARI), CANADA					
	5. SOLE VOTING POWER					
, , , , , , , , , , , , , , , , , , ,	0					
NUMBER OF SHARES	6. SHARED VOTING POWER					
BENEFICIALLY	594,077					
OWNED BY EACH	7. SOLE DISPOSITIVE POWER					
REPORTING						
PERSON WITH	8. SHARED DISPOSITIVE POWER					
	6. SINKED DISTOSITIVE TOWER					
	594,077					
9. AGGREC	ATE AMOUNT BENEFICIALLY OWNED BY EACH R	EPORTING PERSON				
594,077						
	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUD	ES CERTAIN SHARES				
(see instru	ctions)					
11. PERCEN	OF CLASS REPRESENTED BY AMOUNT IN ROW (9	9)				
a so. 1						
7.5% ¹ 12. TYPE OF	REPORTING PERSON (see instructions)					
12. 1112.01	NET ONTHVOT ENSOTV (See instructions)					
СО						
1						
This percentage is calcul-	ted based upon 7,870,209 shares of the Issuer's common s	tock outstanding as of November 3, 2017.				

CUSIP No. 890260409		13G/A	Page 3 of 8 Pages
	OF REPORTING PERSONS ENTIFICATION NOS. OF A	S ABOVE PERSONS (ENTITIES ONLY)	
Steven S	alamon		
	THE APPROPRIATE BOX ructions)	IF A MEMBER OF A GROUP	
(b) □			
3. SEC US	E ONLY		
4. CITIZE	NSHIP OR PLACE OF ORGA	ANIZATION	
ONTAR	IO, CANADA		
	5. SOLE VOTING PC	OWER	
144 OFF OF	0		
NUMBER OF SHARES	6. SHARED VOTING	POWER	
BENEFICIALLY OWNED BY	594,077		
EACH	7. SOLE DISPOSITIV	/E POWER	
REPORTING PERSON WITH	0		
TERSON WITH	8. SHARED DISPOSI	TIVE POWER	
	594,077		
9. AGGRE	GATE AMOUNT BENEFIC	IALLY OWNED BY EACH REPORTIN	G PERSON
594,077			
	IF THE AGGREGATE AMC ructions) □	OUNT IN ROW (9) EXCLUDES CERTA	IN SHARES
11. PERCE	T OF CLASS REPRESENT	ED BY AMOUNT IN ROW (9)	
$7.5\%^{2}$			
	F REPORTING PERSON (se	ee instructions)	
IN			
² This percentage is calcu	lated based upon 7,870,209 sl	hares of the Issuer's common stock outsta	nding as of November 3, 2017.

CUSIP No. 890260409		13G/A	Page 4 of 8 Pages
	OF REPORTING PERSOI ENTIFICATION NOS. OF	NS F ABOVE PERSONS (ENTITIES ONLY)	
	Master Fund L.P.		
		X IF A MEMBER OF A GROUP	
(see instru	ections)		
(a) \Box			
(b) □ 3. SEC USE	OMIV		
3. SEC USE	ONLY		
4. CITIZEN	SHIP OR PLACE OF OR	GANIZATION	
CAYMA	N ISLANDS		
	5. SOLE VOTING I	POWER	
	0		
NUMBER OF SHARES	6. SHARED VOTIN	NG POWER	
BENEFICIALLY	594,077		
OWNED BY EACH	7. SOLE DISPOSIT	TVE POWER	
REPORTING			
PERSON WITH	0		
	8. SHARED DISPO	SITIVE POWER	
	594,077		
9. AGGREC	ATE AMOUNT BENEFI	CIALLY OWNED BY EACH REPORTIN	IG PERSON
594,077			
	F THE AGGREGATE AN	MOUNT IN ROW (9) EXCLUDES CERTA	AIN SHARES
(see instru	actions) \square		
11. PERCEN	Γ OF CLASS REPRESEN	ITED BY AMOUNT IN ROW (9)	
7.5% ³			
	REPORTING PERSON ((see instructions)	
	TIET OTTEN OT ENDOT		
PN			
3			
Inis percentage is calcul	ated based upon 7,870,209	shares of the Issuer's common stock outsta	anding as of November 3, 2017.

Item 1.

- (a) Name of Issuer: TONIX PHARMACEUTICALS HOLDING CORP.
- (b) Address of Issuer's Principal Executive Offices 509 Madison Avenue, Suite 306 New York, New York 10022, United States

Item 2.

(a) Name of Person Filing

Rosalind Advisors, Inc. ("Advisor" to RMF)
Rosalind Master Fund L.P. ("RMF")
Steven Salamon ("President")
Steven Salamon is the portfolio manager of the Advisor which advises RMF.

(b) Address of the Principal Office or, if none, residence

Rosalind Advisors, Inc. 175 Bloor Street East Suite 1316, North Tower Toronto, Ontario M4W 3R8 Canada

Rosalind Master Fund L.P. P.O. Box 309 Ugland House, Grand Cayman KY1-1104, Cayman Islands

Steven Salamon 175 Bloor Street East Suite 1316, North Tower Toronto, Ontario M4W 3R8 Canada

(c) Citizenship

Rosalind Advisors, Inc.: Ontario, Canada

Rosalind Master Fund L.P.: Cayman Islands

Steven Salamon: Ontario, Canada

(d) Title of Class of Securities

Common Stock

(e) CUSIP Number 890260409

Item	3.	If	this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:	
	(a)		Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).	
	(b)		Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).	
	(c)		Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).	
	(d)		Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).	
	(e)		An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);	
	(f)		An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);	
	(g)		A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);	
	(h)		A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);	
	(i)		A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);	
	(j)		Group, in accordance with §240.13d-1(b)(1)(ii)(J).	
Item	4.	o	wnership.	
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.				
(:	a)	A	Amount beneficially owned:	
			Rosalind Master Fund L.P. (RMF) is the record owner of 553,908 shares, and warrants to acquire 40,169 shares of common stock.	
		S	osalind Advisors, Inc. is the investment advisor to and may be deemed to be the beneficial owner of shares held by RMF. teven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial owner of shares held by MF. Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of the shares.	
(1	b)	P	ercent of class:	
			Rosalind Advisors, Inc. – 7.5%	
			Rosalind Master Fund L.P. – 7.5%	
			Steven Salamon – 7.5%	

(c) Number of shares as to which the person has:

(i) Shared power to vote or to direct the vote

Rosalind Advisors, Inc. -594,077Rosalind Master Fund L.P. -594,077

Steven Salamon – 594,077

(ii) Sole power to dispose or to direct the disposition of -0

(iii) Shared power to dispose or to direct the disposition of

Rosalind Advisors, Inc. – 594,077 Rosalind Master Fund L.P. – 594,077

Steven Salamon – 594,077

Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Instruction. Dissolution of a group requires a response to this item.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Item 7–9. Not Applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

2/10/2018
Date

/s/ Steven Salamon
Signature

Steven Salamon/President Rosalind Advisors, Inc.
Name/Title

Joint Filing Agreement

The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of TONIX PHARMACEUTICALS HOLDING CORP. is filed jointly, on behalf of each of them.

Rosalind Advisors, Inc.

By: /s/ Steven Salamon Name: Steven Salamon Title: President

Rosalind Master Fund L.P.

By: /s/ Mike McDonald

Name: Mike McDonald

Title: Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)